Tabula Rasa HealthCare (NASDAQ:TRHC) has earned a consensus rating of “Buy” from the fourteen ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $36.22.
A number of analysts have recently commented on TRHC shares. Zacks Investment Research lowered shares of Tabula Rasa HealthCare from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Citigroup started coverage on shares of Tabula Rasa HealthCare in a research note on Thursday, January 4th. They issued a “buy” rating for the company. Chardan Capital reiterated a “buy” rating and issued a $50.00 price target (up from $46.00) on shares of Tabula Rasa HealthCare in a research note on Friday, March 16th. BidaskClub lowered shares of Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research report on Wednesday, February 21st. Finally, Oppenheimer boosted their target price on shares of Tabula Rasa HealthCare from $35.00 to $47.00 and gave the company an “outperform” rating in a research report on Tuesday, March 13th.
Shares of TRHC stock traded down $0.43 during trading hours on Wednesday, reaching $40.95. The company had a trading volume of 282,193 shares, compared to its average volume of 357,435. Tabula Rasa HealthCare has a one year low of $11.59 and a one year high of $41.90. The firm has a market capitalization of $811.95, a PE ratio of -1,023.75, a P/E/G ratio of 9.02 and a beta of 2.39. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 0.01.
Tabula Rasa HealthCare (NASDAQ:TRHC) last announced its quarterly earnings results on Monday, March 12th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.03). Tabula Rasa HealthCare had a negative return on equity of 1.96% and a net margin of 10.63%. The company had revenue of $43.93 million during the quarter, compared to the consensus estimate of $38.91 million. During the same quarter in the prior year, the firm earned $0.10 earnings per share. The business’s revenue was up 60.9% compared to the same quarter last year. analysts anticipate that Tabula Rasa HealthCare will post 0.18 earnings per share for the current year.
In other Tabula Rasa HealthCare news, Director Bruce Luehrs sold 252,242 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $34.29, for a total value of $8,649,378.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Calvin H. Knowlton sold 8,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $34.75, for a total transaction of $278,000.00. The disclosure for this sale can be found here. Insiders have sold 324,000 shares of company stock valued at $11,309,958 over the last 90 days. 45.80% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN boosted its position in shares of Tabula Rasa HealthCare by 79.8% in the third quarter. Wells Fargo & Company MN now owns 12,768 shares of the company’s stock worth $341,000 after purchasing an additional 5,668 shares during the period. JPMorgan Chase & Co. bought a new position in shares of Tabula Rasa HealthCare in the third quarter worth approximately $563,000. EAM Investors LLC boosted its position in shares of Tabula Rasa HealthCare by 21.5% in the fourth quarter. EAM Investors LLC now owns 178,588 shares of the company’s stock worth $5,009,000 after purchasing an additional 31,596 shares during the period. Pier Capital LLC boosted its position in shares of Tabula Rasa HealthCare by 33.3% in the fourth quarter. Pier Capital LLC now owns 206,905 shares of the company’s stock worth $5,804,000 after purchasing an additional 51,673 shares during the period. Finally, Quadrant Private Wealth Management LLC bought a new position in shares of Tabula Rasa HealthCare in the fourth quarter worth approximately $569,000. Institutional investors and hedge funds own 47.27% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/18/tabula-rasa-healthcare-trhc-receives-36-22-consensus-target-price-from-brokerages.html.
Tabula Rasa HealthCare Company Profile
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. The company provides patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to enhance patient outcomes, reduce hospitalizations, lower healthcare costs, and manage risk.
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.